Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
Clinical trial NCT06634667 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06634667
- Sponsor
- Hunan Province Tumor Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-30
- Primary completion
- 2026-08-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.